Which states have published rules about TB-500?

As of 2026-11-20, 2 states have published sentences naming TB-500: Alabama, Kentucky. 5 more (Maryland, Mississippi, Missouri, South Carolina, Utah) have rules about a whole class of drugs that TB-500 falls into, without naming it. We read the boards of 44 states every night. In 6 more we read statutes and rules only, so silence there tells you less.

See TB-500 on the map

The states that have published

Alabama

Coverage is limited to the six peptide identities and their specified administration routes: Peptide Covered form Covered route or dosage form BPC-157 Acetate Subcutaneous, intramuscular, oral, and topical TB-500 Acetate Subcutaneous or intramuscular injection Epitalon Acetate Subcutaneous or intramuscular injection, dispensed in intermittent courses Semax Free base Intranasal KPV Acetate Topical and oral MOTS-c Acetate Subcutaneous or intramuscular injection *Acetate refers to a common salt form of the peptide.

AL medical board: Hhs enforcement discretion policy regarding 503a compounding using certain peptide bulk drug substances. Read it on the source · last read 2026-11-20 The same sentence is also on AL medical board: FAQs HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.

Kentucky

New rule found, see quote

Do not compound any preparation for human use from BPC-157, TB-500, Epitalon, Semax, KPV or MOTS- c, whether for an individual patient, office use or any other purpose.

KY pharmacy board: Frankfort, Ky. (November 19, 2026) Compliance Alert: Compounding With Peptide Bulk Drug Substances Under the HHS Enforcement Discretion Policy. Read it on the source · last read 2026-11-20

The six substances are BPC-157, TB-500 (thymosin beta-4 fragment), Epitalon, Semax, KPV and MOTS-c.

KY pharmacy board: Frankfort, Ky. (November 19, 2026) Compliance Alert: Compounding With Peptide Bulk Drug Substances Under the HHS Enforcement Discretion Policy. Read it on the source · last read 2026-11-20

Rules that reach TB-500 without naming it

These are about a whole class of drugs, such as any drug a practitioner prescribes. Each says which class beside it.

Maryland

A telehealth practitioner may not treat a patient or prescribe medication based solely on a static online questionnaire.

MD COMAR 10.32.05, telehealth (Division of State Documents bulk XML). This is a rule about any drug a practitioner prescribes. TB-500 is one, so it applies. The rule does not name TB-500. Read it on the source · last read 2026-11-10

Mississippi

New rule found, see quote

Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non- FDA approved or research-grade peptide to a patient.

MS pharmacy board: Joint Statement on the Prescribing of Non-FDA Approved (Research-Grade) Peptides. This is a rule about a peptide sold as research-grade or not eligible under FDA's rules. TB-500 is one, so it applies. The rule does not name TB-500. Read it on the source · last read 2026-11-20

Missouri

No health care provider, as defined in section 376.1350 , shall prescribe any drug, controlled substance, or other treatment to a patient based solely on an evaluation through telemedicine; except that, a physician or such physician's on-call designee, or an advanced practice registered nurse, a physician assistant, or an assistant physician in a collaborative practice arrangement with such physician, may prescribe any drug, controlled substance, or other treatment that is within his or her scope of practice to a patient based solely on a telemedicine evaluation if a previously established and ongoing physician-patient relationship exists between such physician and the patient being treated.

MO Revised Statutes 334.108. This is a rule about any drug a practitioner prescribes. TB-500 is one, so it applies. The rule does not name TB-500. Read it on the source · last read 2026-11-10

South Carolina

New rule found, see quote

All drugs administered or dispensed to a patient must be prescription/pharmaceutical quality; therefore, under no circumstances is it permissible for a physician to compound, administer, prescribe, or dispense research-grade or FDA-ineligible peptides to a patient.

SC medical board: BME Notice re Peptides. This is a rule about a peptide sold as research-grade or not eligible under FDA's rules. TB-500 is one, so it applies. The rule does not name TB-500. Read it on the source · last read 2026-11-20

Utah

New rule found, see quote

DOPL will apply enforcement discretion only when each condition listed in the HHS interim policy is met.

UT Division of Professional Licensing: Peptide Enforcement Discretion Policy (30 October 2026). This is a rule about one of the six peptides in HHS's 503A enforcement discretion policy of 30 October 2026. TB-500 is one, so it applies. The rule does not name TB-500. Read it on the source · last read 2026-11-20

Every state

Nothing on record means we have found no sentence naming TB-500 in what that state publishes. It is not permission.

StateWhat its own sources say about TB-500What we read
AlabamaOne sentence naming it, quoted aboveBoard and laws, 11 of 11 sources answered
AlaskaNothing on recordLaws only: we do not read this board's own guidance. 2 of 5 sources answered
ArizonaNothing on recordBoard and laws, 4 of 6 sources answered
ArkansasNothing on recordBoard and laws, 4 of 4 sources answered
CaliforniaNothing on recordBoard and laws, 4 of 4 sources answered
ColoradoNothing on recordLaws only: we do not read this board's own guidance. 1 of 5 sources answered
ConnecticutNothing on recordBoard and laws, 4 of 4 sources answered
DelawareNothing on recordBoard and laws, 4 of 4 sources answered
FloridaNothing on recordBoard and laws, 6 of 6 sources answered
GeorgiaNothing on recordBoard and laws, 3 of 3 sources answered
HawaiiNothing on recordBoard and laws, 5 of 5 sources answered
IdahoNothing on recordBoard and laws, 4 of 4 sources answered
IllinoisNothing on recordBoard and laws, 1 of 1 source answered
IndianaNothing on recordBoard and laws, 2 of 2 sources answered
IowaNothing on recordBoard and laws, 3 of 3 sources answered
KansasNothing on recordBoard and laws, 3 of 5 sources answered
Kentucky2 sentences naming it, quoted aboveBoard and laws, 5 of 5 sources answered
LouisianaNothing on recordBoard and laws, 4 of 4 sources answered
MaineNothing on recordBoard and laws, 4 of 6 sources answered
MarylandNothing naming it. A rule about a class it falls into, quoted aboveBoard and laws, 4 of 4 sources answered
MassachusettsNothing on recordLaws only: we do not read this board's own guidance. 5 of 7 sources answered
MichiganNothing on recordBoard and laws, 4 of 6 sources answered
MinnesotaNothing on recordBoard and laws, 11 of 11 sources answered
MississippiNothing naming it. A rule about a class it falls into, quoted aboveBoard and laws, 6 of 7 sources answered
MissouriNothing naming it. A rule about a class it falls into, quoted aboveBoard and laws, 12 of 12 sources answered
MontanaNothing on recordBoard and laws, 2 of 2 sources answered
NebraskaNothing on recordBoard and laws, 2 of 2 sources answered
NevadaNothing on recordBoard and laws, 3 of 3 sources answered
New HampshireNothing on recordBoard and laws, 5 of 7 sources answered
New JerseyNothing on recordLaws only: we do not read this board's own guidance. 3 of 7 sources answered
New MexicoNothing on recordBoard and laws, 5 of 5 sources answered
New YorkNothing on recordBoard and laws, 2 of 2 sources answered
North CarolinaNothing on recordBoard and laws, 3 of 3 sources answered
North DakotaNothing on recordBoard and laws, 5 of 5 sources answered
OhioNothing on recordBoard and laws, 4 of 4 sources answered
OklahomaNothing on recordBoard and laws, 1 of 1 source answered
OregonNothing on recordBoard and laws, 3 of 3 sources answered
PennsylvaniaNothing on recordBoard and laws, 2 of 2 sources answered
Rhode IslandNothing on recordLaws only: we do not read this board's own guidance. 4 of 5 sources answered
South CarolinaNothing naming it. A rule about a class it falls into, quoted aboveBoard and laws, 4 of 4 sources answered
South DakotaNothing on recordBoard and laws, 10 of 11 sources answered
TennesseeNothing on recordBoard and laws, 7 of 8 sources answered
TexasNothing on recordBoard and laws, 3 of 3 sources answered
UtahNothing naming it. A rule about a class it falls into, quoted aboveBoard and laws, 6 of 6 sources answered
VermontNothing on recordBoard and laws, 5 of 5 sources answered
VirginiaNothing on recordLaws only: we do not read this board's own guidance. 6 of 6 sources answered
WashingtonNothing on recordBoard and laws, 4 of 4 sources answered
West VirginiaNothing on recordBoard and laws, 3 of 3 sources answered
WisconsinNothing on recordBoard and laws, 5 of 5 sources answered
WyomingNothing on recordBoard and laws, 6 of 6 sources answered

The federal position, which applies in every state

Federal sentences are shown here once, separately from what each state published.

FDA published safety risks
Thymosin beta-4, fragment (LKKTETQ), also known as TB-500 Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impu

FDA, same page, table headed "Bulk drug substances nominated but withdrawn": previously in category 2, withdrawn by the nominators. Read it on the source

HHS policy for 503A compounding
Until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list, HHS does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance that is not a component of an FDA-approved drug product, the subject of an applicable USP or NF monograph, or on the 503A bulks list codified at 21 CFR 216.23(a), when all of the following circumstances are present:
The 10 conditions, as the policy writes them
  1. 503A Interim Access List. The peptide bulk drug substance appears in Appendix A to this policy.
  2. Identity of the Peptide Bulk Drug Substance. The peptide bulk drug substance has the identity and limitations in route of administration described in Appendix B. The identity includes but is not limited to amino acid sequence, chemical structure, molecular weight, and molecular formula.
  3. Characterization. The bulk drug substance is from a facility registered under section 510 (21 U.S.C. § 360) and characterized and identified in a valid certificate of analysis (COA) that includes test results consistent with existing guidance-based criteria described by FDA (see Appendix B). This helps provide assurance that what a compounder receives from a supplier is what it claims to be and has been tested for identity, purity, potency, and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination, and impurities.
  4. The original manufacturer of the bulk drug substance (not a subsequent packer, repacker, labeler, or distributor) is registered with FDA under section 510, is in compliance with CGMP and other FD&C requirements and the physical location of the facility is listed on the COA provided to the 503A compounder. If the peptide bulk drug substance is obtained through an FDA-registered repacker, relabeler, or reseller, that entity has itself performed and documented appropriate vendor validation of the bulk drug substance manufacturer and validation of the manufacturer's COA.
  5. Report products compounded, serious adverse events, and product quality issues to FDA and to the States where the products are compounded and sent (if different). Compounders report serious adverse events associated with the use of the compounded drug product in humans (regardless of whether or not considered drug related) and product quality issues (e.g., information concerning any bacteriological contamination, or any significant chemical, physical, or other change in the distributed drug product, or any failure of a product to meet applicable specifications) to FDA's MedWatch Safety Information and Adverse Event Reporting Program. This provides an opportunity for FDA and States to act on emerging risks. In addition, the procedure for reporting adverse events and issues with the identity, strength, purity, and/or quality of the product should be detailed on the product labeling provided to the patient. Product reporting for the compounder includes the following
    • a. Active ingredient and strength of active ingredient per unit;
    • b. Original manufacturer of the active ingredient, including unique facility identifier for the manufacturing facility; and
    • c. Dosage form and route of administration.
  6. Product labeling. Product labeling that includes the following statement: "This is a compounded drug product. Not for resale."
  7. The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A. It will be easier to attribute adverse events or clinical outcomes to a specific substance, which is essential for meaningful safety surveillance and signal detection, if compounded peptide products include a single API.
  8. Route of administration. Achieving adequate oral bioavailability of peptides is inherently difficult and complex. Therefore, if a peptide is compounded in an oral dosage form, the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.
  9. Drug delivery device. The only drug delivery device co-packaged or containing the compounded drug is an FDA 510(k)-cleared syringe. More complex drug delivery devices introduce additional patient risk.
  10. The drug product is compounded in compliance with all other applicable requirements of the FD&C Act including that the drug product not be compounded under insanitary conditions (21 U.S.C. § 351(a)(2)(A)) and section 503A's (21 U.S.C. 353a) patient specific prescription requirement.
Based on the identified updated information, enforcement discretion for TB-500 acetate appropriate for subcutaneous or intramuscular injectable dosage forms that are compounded from API accompanied by a CoA meeting the conditions of this policy.

HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Read it on hhs.gov · copy obtained 2026-11-05

We report what each source says, in its own words. We do not give legal advice. Nothing on record is not permission.

Every state's sources were last read on 2026-11-20. This page is rebuilt from them each time it loads.